Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
7(54%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
23%
Ph phase_3
5
38%
Ph not_applicable
2
15%
Ph phase_4
1
8%
Ph early_phase_1
1
8%
Ph phase_2
1
8%

Phase Distribution

4

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
1(7.7%)
Phase 3Large-scale testing
5(38.5%)
Phase 4Post-market surveillance
1(7.7%)
N/ANon-phased studies
2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

13

all time

Status Distribution
Active(9)
Completed(2)
Other(2)

Detailed Status

Recruiting5
Active, not recruiting2
Completed2
unknown2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
13
Active
7
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (7.7%)
Phase 13 (23.1%)
Phase 21 (7.7%)
Phase 35 (38.5%)
Phase 41 (7.7%)
N/A2 (15.4%)

Trials by Status

active_not_recruiting215%
completed215%
unknown215%
recruiting538%
not_yet_recruiting215%

Recent Activity

7 active trials
Showing 5 of 13
recruitingphase_4

Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus

NCT05898308
recruitingearly_phase_1

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

NCT04161248
recruitingphase_3

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

NCT06929624
not_yet_recruitingphase_3

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

NCT07187960
recruitingphase_3

Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)

NCT06341205
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT05898308Phase 4

Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus

Recruiting
NCT04161248Early Phase 1

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Recruiting
NCT06929624Phase 3

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Recruiting
NCT07187960Phase 3

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Not Yet Recruiting
NCT06341205Phase 3

Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)

Recruiting
NCT07071246Not Applicable

Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis

Active Not Recruiting
NCT05329090Phase 3

Evaluation of Glucocorticoids Plus Rituximab in Patients with Newly-Diagnosed or Relapsing IgA Vasculitis

Active Not Recruiting
NCT06792253Phase 3

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
NCT06164327Phase 1

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Unknown
NCT04224571Phase 2

CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Completed
NCT05990985Not Applicable

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Not Yet Recruiting
NCT03072199Phase 1

Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study

Completed
NCT03980379Phase 1

Pharmacokinetics, Efficacy and Safety of the 304 Injection

Unknown

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13